Pembrolizumab is approved for the first-line therapy of squamous and non-squamous cell NSCLC patients with programmed cell death ligand-1 (PD-L1) of at least 50 ...

Treatment options for squamous cell lung cancer · Surgery · Radiation therapy · Chemotherapy · Angiogenesis inhibitors · Immunotherapy.

Current studies have confirmed an expanding role for immunotherapy, a potential opportunity for VEGFR inhibition, and even future targets in FGFR and PI3K-AKT ...

In 2015, the FDA approved necitumumab, a fully human IgG1 anti-EGFR monoclonal antibody, in combination with gemcitabine and cisplatin for the first-line ...

Immunotherapy for lung cancer, alone or in combination with conventional treatments, can significantly improve outcomes for patients fighting lung cancer.

28 нояб. 2022 г. · Our results found that first-line immunotherapy can increase DCR to 86.7% and ORR to 46.7%, which is similar to other clinical studies. In ...

21 февр. 2023 г. · The present article encompasses a detailed overview of the recent developments in the immunotherapeutic landscape in targeting small cell lung cancer (SCLC) ...

17 мая 2019 г. · Pembrolizumab monotherapy (PD-L1 TPS ≥ 50%) and carboplatin plus taxane plus pembrolizumab combinatorial therapy are new first-line standards of care.

4 нояб. 2024 г. · The three main types of immunotherapy for lung cancer are checkpoint inhibitors, cancer vaccines, and CAR T-cell therapy. Immunotherapy Treatment · Types · Success Rates

Some people with lung cancer have immunotherapy. Immunotherapy helps to strengthen or restore the immune system's ability to fight cancer.